Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2232-2242

  Horton, Terzah M ^a,d   Jenkins, Gaye ^a   Pati, Debananda ^a   Zhang, Linna ^a   Dolan, M Eileen ^b   Ribes Zamora, Albert ^a   Bertuch, Alison A ^a   Blaney, Susan M ^a   Delaney, Shannon L ^b   Hegde, Madhuri ^c   Berg, Stacey L ^a  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CYTOTOXICITY; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MISMATCH REPAIR; MYELOID LEUKEMIA; NONHOMOLOGOUS END JOINING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; CELL LINE, TUMOR; DACARBAZINE; DNA MISMATCH REPAIR; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LEUKEMIA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 68849128273     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0142     Document Type: Article

References (49)

1. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
2. Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 2003;25:372-8.
3. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002;20:3249-53.
4. Horton TM, Thompson PA, Berg SL, et al. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol 2007;25:4922-8.
5. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400.
6. 6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest 1985;76:2106-14.
7. Lewis C, Low JA. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2007;8:1051-6.
8. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995;9:1888-95.
9. Gu L, Cline-Brown B, Zhang F, Qiu L, Li GM. Mismatch repair deficiency in hematological malignancies with microsatellite instability. Oncogene 2002;21:5758-64.
10. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996;56:5375-9.
11. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999;5:2908-17.
12. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8.
13. Tentori L, Portarena I, Vernole P. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol 2001;47:361-9.
14. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 2002;40:44-54.
15. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005;4:1364-8.
16. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma and lymphomas. Clin Cancer Res 2003;9:5370-9.
17. Miknyoczki SJ, Jones-Bolin S, Pritchard S. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
18. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
19. Curtin NJ, Wang LZ, Yiakouvaki A, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004;10:881-9.
20. Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003;9:2711-8.
21. Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002;99:2241-4.
22. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
23. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42.
24. Kummar S, Kinders R, Gutierrez M, et al. Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a phase 0 trial. J Clin Oncol 2007;25:3518a.
25. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006;58:13-23.
26. Greco WR, Park HS, Rustum YM. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 1990;50:5318-27.
27. 6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 1998;16:1803-10.
28. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
29. Suraweera N. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats. Gastroenterology 2002;123:1804-11.
30. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 2000;46:507-16.
31. Hangaishi A, Ogawa S, Mitani K, et al. Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines. Blood 1997;89:1740-7.
32. Ribeiro EM, Rodriguez JM, Coser VM. Microsatellite instability and cytogenetic survey in myeloid leukemias. Braz J Med Biol Res 2002;35:153-9.
33. Hosoya N, Hangaishi A, Ogawa S, et al. Frameshift mutations of the hMSH6 gene in human leukemia cell lines. Jpn J Cancer Res 1998;89:33-9.
34. Pati D, Haddad BR, Haegele A, et al. Hormone-induced chromosomal instability in p53-null mammary epithelium. Cancer Res 2004;64:5608-16.
35. Smeaton MB, Miller PS, Ketner G, Hanakahi LA. Small-scale extracts for the study of nucleotide excision repair and non-homologous end joining. Nucleic Acids Res 2007;35:e152. Epub 2007 Dec 10.
36. Dhodapkar M, Rubin J, Reid JM. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3:1093-100.
37. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178-87.
38. 6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 2005;23:7646-53.
39. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
40. Wang M, Wu W, Rosidi B, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006;34:6170-82.
41. Tentori L, Lacal PM, Benincasa E, et al. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 1998;285:884-93.
42. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56.
43. Mason KA, Valdecanas D, Hunter NR, Milas L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 2008;26:1-5.
44. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005;7:1-20.
45. Das-Gupta EP, Seedhouse CH, Russell NH. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol 2001;114:307-12.
46. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996;74:1030-6.
47. 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005;11:3402-9.
48. Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells. EMBO J 2006;25:1305-14.
49. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.